McVie J G
Scientific Department, Cancer Research Campaign, London, UK.
Semin Oncol. 1996 Jun;23(3 Suppl 7):12-4.
The recent meta-analysis of 52 trials evaluating outcomes of non-small cell lung cancer patients treated with various modalities is discussed. From these data, three priorities can be proposed: (1) lung cancer physicians should alter their practices to include cisplatin-containing combination chemotherapy in their management protocols, (2) many more patients with lung cancer should be entered into clinical trials, and (3) the reporting of trial data, both response and toxicity data and quality of life assessments, needs to be improved. In addition, the poor outcome of non-small cell lung cancer patients, even those with the smallest volume of disease at the time of diagnosis, emphasizes the need for application of more aggressive treatments at the earliest possible stage of disease and the need for continued new drug development.
本文讨论了最近一项对52项评估非小细胞肺癌患者不同治疗方式疗效的试验的荟萃分析。基于这些数据，可以提出三个优先事项：（1）肺癌医生应改变其治疗方式，在管理方案中纳入含顺铂的联合化疗；（2）应该让更多肺癌患者参与临床试验；（3）试验数据的报告，包括反应和毒性数据以及生活质量评估，都需要改进。此外，非小细胞肺癌患者的预后较差，即使是那些在诊断时疾病体积最小的患者，这凸显了在疾病的最早阶段应用更积极治疗的必要性以及持续进行新药研发的必要性。
